Baxalta Inc

Baxalta — Merger or Acquisition (January 2016)

26 slides from Baxalta's merger presentation, Jan 11, 2016

  1. Slide 1: Forward Looking Statements and Other Matters

    Forward Looking Statements and Other Matters Forward-Looking Statements Statements included herein that are not historical facts, including without limitation statements concerning our proposed business combination with Baxalta Incorporated (“Baxalta”) and the timing and financial and strategic bene

  2. Slide 2: Forward Looking Statements and Other Matters (cont'd)

    Forward Looking Statements and Other Matters (cont’d) Additional Information This communication does not constitute an offer to buy or solicitation of any offer to sell securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. This c

  3. Slide 3: Transaction Highlights

    Transaction Highlights • Baxalta shareholders will receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire closing ADS price of January 8, 2016 implies a value of $45.57 per Baxalta share – – Represents an aggregate consideration of approximately $32 billion Baxalta shareholder

  4. Slide 4: Proposed combination would create the global leader in rare diseases

    Proposed combination would create the global leader in rare diseases with compelling financials and a strong outlook balance and # diseases by geographies and future growth rate of 16-17% in synergies GAAP earnings in >50 rare diseases >30 planned with ~$5B sales 5 (1) Therapeutic Area. (2) Based on

  5. Slide 5: Focused strategy to drive sustainable therapeutic innovation and shareholder value creation

    Focused strategy to drive sustainable therapeutic innovation and shareholder value creation Shire’s strategy is generating improved patient outcomes and shareholder returns Combined company will accelerate growth and innovation commercial excellence and M&A Growth Innovation Efficiency People 6 Acce

  6. Slide 6: Combination enhances category leadership in rare diseases

    Combination enhances category leadership in rare diseases Combined rare diseases platform Rigosertib Pacritinib SM101 SHP609 SHP631 SHP611 SHP635 SHP623 SHP637 BAX 069 # 1diseases (4) DX2930 in rare (4) Calaspargase pegol SHP627 ~$13B in 2020 rare diseases revenue(1); >50 products / programs(2) SHP6

  7. Slide 7: Eight leading franchises each with best-in-class products

    Eight leading franchises each with best-in-class products Positioned for sustained TA leadership Baxalta Shire (1) Pending completion of Dyax acquisition (2) Subject to regulatory approvals. (3) Launching 2H 2016 (4) Proforma 2015 revenues for Oncaspar (5) Launching 2016. Source: Analyst consensus a

  8. Slide 8: Double-digit top-line growth and increasing focus on rare diseases

    Double-digit top-line growth and increasing focus on rare diseases of revenue from rare diseases >$20B Rare diseases Shire Baxalta Combined 2020E(2) Shire Baxalta Combined 2015E(1) 2015E(1) 2015E(1) (1) Based on Shire and Baxalta company guidance. (2) Based on Shire management projections. 9 ~11% CA

  9. Slide 9: Baxalta brings clear leadership in hematology

    Baxalta brings clear in hematology and sustainable leadership 2015E Market Share in hemophilia and hematology(1) Baxalta has the broadest hemophilia portfolio Inhibitor therapies Select products Hemophilia A Hemophilia B ~$12B ~$9B ~$6B Other Biogen Pfizer CSL Novo Nordisk Alexion Bayer Baxalta Beni

  10. Slide 10: Continued growth and innovation opportunities in the hemophilia market

    Continued growth and innovation opportunities in the hemophilia market Global Hemophilia Market Revenues(1) ($M) 11,033 10,494 9,970 9,440 Segment growth driven by innovation and global reach Increasing diagnosis rates, especially in developing countries Increasing adoption of prophylaxis, currently

  11. Slide 11: Well positioned for sustained leadership in hemophilia

    Well positioned for sustained leadership in hemophilia Next generation of innovations(1) Near term best-in-class growth drivers Current standards of hemophilia care • Leadership position in terms of share, breadth, and innovation Advate recognized as best-in-class rFVIII with ~50% share advantage vs

  12. Slide 12: Hemophilia franchise provides core for building a broader hematology and oncology business

    Hemophilia franchise provides core for building a broader hematology and oncology business Hemophilia Broader Hematology and Oncology 13 Calaspargase pegol BAX 069 BAX 888 BAX 817 BAX 930 Rigosertib Pacritinib BAX 826 BAX 335

  13. Slide 13: Breadth, established position, and innovation propel immunoglobulins (IG) business

    Breadth, established position, and innovation propel immunoglobulins (IG) business Baxalta’s Broad IG Portfolio The Only Once-A-Month IGSC Future Flagship Brand Expanding Baxalta’s IGSC Platform With 20% Concentration Baxalta’s Cornerstone IG brand The Only IgA < 1 m g/ml Baxalta’s Platform for Grow

  14. Slide 14: Robust combined pipeline of innovative rare disease programs

    Robust combined pipeline of innovative rare disease programs with near- and long-term potential Preclinical Phase 1 Phase 2 Firazyr Phase 3(3) Registration DX2930 (1)(6) 27 Research programs SHP630 adRP SHP636 MRT for CF SHP637 MRT for UCD SHP623 (rC1-INH) HAE prophylaxis TH / GCH1 Gene pod Parkinso

  15. Slide 15: Multiple recent and upcoming pipeline catalysts

    Multiple recent and upcoming pipeline catalysts Selected events Intuniv EU approval (Sept 2015) Adynovate (Nov 2015) and Vonvendi (Dec 2015) FDA approval Obizur EU approval (Nov 2015) Pacritinib FDA filing EU filing of Onivyde Positive Phase 3 results for lifitegrast (OPUS 3) Fast-track designation

  16. Slide 16: Combined rare diseases capabilities create industry-leading platform for future growth

    Combined rare diseases capabilities create industry-leading platform for future growth opportunities Cutting-edge, flexible manufacturing Specialized research and development expertise Targeted, high-touch go-to-market model Industry leading capability to drive growth of rare and specialty products

  17. Slide 17: Transaction delivers significant shareholder value

    Transaction delivers significant shareholder value • Double-digit top-line compound annual growth • #1 rare diseases company by revenue • TA leadership positions with best-in-class products • Significant operating synergies • Combined effective Non-GAAP tax rate of 16-17% expected in 2017, and beyon

  18. Slide 18: Financial highlights

    Financial highlights • Double-digit top-line growth • Expected to be accretive to Non-GAAP diluted EPS in 2017, the first full calendar year of ownership, and beyond Expect combined annual operating cash flow of approximately $6B beginning in 2018 • • Attractive ROIC; projected to exceed Shire cost

  19. Slide 19: Significant synergy opportunity

    Significant synergy opportunity >$500M Annual cost synergies projected by end of year 3 16-17% Combined effective Non-GAAP tax rate achieved by year-end 2017 Accelerated growth through combined capabilities and global infrastructure • Lever increased scale across global commercial footprint • Presen

  20. Slide 20: Combination creates diversification and optionality for the new enterprise

    Combination creates diversification and optionality for the new enterprise • Increased revenue diversification • Geographic distribution mitigates pricing, political, reimbursement risks • Lifecycle balance and IP portfolio with long-duration assets mitigate future LOEs • Expanded range of therapeut

  21. Slide 21: Strong record of integration and accelerating growth

    Strong record of integration and accelerating growth 2013 2014 2015 22 (1) Dyax acquisition announced 2 Nov 2015. 30-year history of growth and superior financial results fueled by effective identification and integration of strategic acquisitions (1) integration planning Pending acquisition; on tra

  22. Slide 22: Compelling opportunity for shareholders of both companies

    Compelling opportunity for companies shareholders of both • Accelerated strategic plan including leading positions in two new rare disease categories and an emerging position in oncology • Immediate significant premium • Acceleration and diversification of Baxalta’s strategy • Enhanced growth trajec

  23. Slide 23: And benefits key stakeholders beyond investors

    And benefits key stakeholders beyond investors 24 (1) Largest by revenue. For employees – rewarding opportunity for growth • Develop and deliver innovative therapies for patients in need • Entrepreneurial biotech culture with career growth opportunities • Individuals valued and rewarded for their co

  24. Slide 24: Summary

    Summary 25 Delivers portfolio diversification and optionality Provides compelling financial profile and value creation Delivers TA leadership with best-in-class products and franchises Immediately creates the global leader in rare diseases

  25. Slide 25: Non-GAAP financial measures

    Non-GAAP financial measures This presentation contains financial measures not prepared in accordance with US GAAP. These Non-GAAP measures exclude the effect of certain cash and non-cash items, that Shire's management believes are not related to the core performance of Shire’s business. These Non-GA

  26. Slide 26: Non-GAAP financial measures

    Non-GAAP financial measures ‘This presentation contains financial measures not prepared in accordance with US GAAP. These Hlon GAAP measures exclude the effect of certain cash and non-cash toms, that She's ‘management beleves are not elated tote core performance of Site's business. ‘These Non-GAAP f

Baxalta — Merger or Acquisition (January 2016) on 6ix